Therapeutic cancer vaccine targeted to HAAH (aspartyl-[asparaginyl]-beta-hydroxylase
AssigneePanacea Pharmaceuticals, Inc.
InventorsBiswajit Biswas, Carl R. Merril, Hossein Ghanbari
Life of this patent
Estimating the term…
Abstract
The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
Claims6
A nucleic acid construct comprising at least one nucleotide sequence encoding an amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase and a nucleotide sequence encoding bacteriophage lambda head decoration protein D (gpD), wherein the amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase is the amino acid sequence of SEQ ID NO:
- 7.
A nucleic acid construct comprising at least one nucleotide sequence encoding an amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase and a nucleotide sequence encoding gpD, wherein the amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase is the amino acid sequence of SEQ ID NO:
- 8.
A nucleic acid construct comprising at least one nucleotide sequence encoding an amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase and a nucleotide sequence encoding gpD, wherein the amino acid sequence native to Aspartyl-[Asparaginyl]-β-hydroxylase is the amino acid sequence of SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.